Dermatology and plastic surgery together accounted for 74% of all foreign patient visits to Korea, according to data reported by Korea Biomedical Review — a concentration that underscores how thoroughly aesthetic medicine now defines the country's medical tourism sector.

The figure is striking less for its existence than for its magnitude. Three of every four encounters between a foreign patient and a Korean clinician occur in one of two fields, and both are procedural, cash-pay, and largely elective. Internal medicine, orthopedics, oncology and other high-acuity specialties share the remaining quarter of the market.

Why does the 74% figure matter for dermatology?

For dermatologists outside Korea, the statistic is a market signal rather than a clinical one. It quantifies what has long been observed anecdotally: Korea has become the global reference point for cosmetic dermatology at scale. Patients are not traveling for biologics or complex medical dermatology. They are traveling for procedures — and they are paying out of pocket.

That demand pattern has practice-level consequences. Aesthetic dermatology in Korea operates in a competitive, high-volume environment where pricing pressure, rapid technology adoption and patient throughput shape clinical norms in ways that differ sharply from regulated Western reimbursement systems. For practices competing for the same internationally mobile patients, the Korean benchmark on price and service intensity is already part of the conversation.

What drives the concentration?

The report points to a market built almost entirely on appearance-related care. Several structural factors explain why dermatology and plastic surgery dominate:

• Cultural and media visibility of Korean aesthetic standards, reinforced globally through entertainment exports
• Dense clustering of dermatology and plastic surgery clinics in Seoul districts such as Gangnam, which function as de facto medical tourism hubs
• Cash-pay pricing that avoids the friction of cross-border insurance claims
• Short recovery pathways for many aesthetic procedures, compatible with travel itineraries

The concentration also reflects a self-reinforcing cycle: high patient volume supports clinic investment, which in turn attracts more foreign patients seeking the latest devices and techniques.

What are the implications for access and regulation?

A market this concentrated carries vulnerabilities. If three-quarters of foreign patient revenue sits in two specialties, policy shifts — tightened visa rules for medical travel, changes in advertising regulation for cosmetic procedures, or post-procedure complication disputes — would hit the sector asymmetrically.

There is also a quality-of-care question that dermatology readers will recognize. High-volume aesthetic practice serving non-Korean-speaking patients raises documented pain points: informed consent across language barriers, follow-up care after the patient flies home, and management of complications that present to clinicians in the patient's country of origin. Dermatologists in the United States and Europe increasingly see themselves as the downstream recipients of that care gap.

The 74% share also invites scrutiny of how Korea's regulators and professional societies manage standards in a market where foreign demand is a core revenue stream. Medical tourism growth in aesthetic specialties has historically outpaced the development of accreditation frameworks tailored to international patients.

What should practices outside Korea take from it?

The figure is a competitive data point. Patients who research aesthetic procedures online are comparing Korean clinic pricing and offerings against domestic options as a matter of course, whether or not they ultimately travel. Practices that ignore the international price and service benchmark in aesthetic dermatology are pricing in a market that no longer exists.

At the same time, the concentration of demand in Korea highlights an opening for domestic practices: patients who want Korean-caliber aesthetic results without travel represent a retention opportunity — provided practices can match the service model, not just the clinical outcome.

The Korea Biomedical Review data make clear that dermatology is not a peripheral player in medical tourism; in Korea it is, together with plastic surgery, essentially the entire market. Whether that concentration holds as other countries build competing aesthetic-medicine hubs will shape referral flows and pricing in cosmetic dermatology well beyond Seoul.